The present paper indicates that selected chemokines and their receptors, VEGF and EGFR, DNA- and RNA-based biomarkers, and MET, IL-6 and CRP, as well as MMPs and their tissue inhibitors, are promising biomarkers in the diagnosis and progression of GC, while selected ADAMs and TIMPs might be used as potential prognostic factors of a GC patient survival. This evidence concerns the gene IL6 and gastric cancer.